Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

EU-Wide Staggered Release Planned

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Concept of a human head with a puzzle in the middle.
(Shutterstock)

Eisai plans to launch Leqembi (lecanemab) in Germany and Austria in fiscal year 2025 and will stagger the drug’s launch in other EU countries over the next few years, following the approval of the early Alzheimer’s disease (AD) drug by the European Commission.

Leqembi, which Eisai co-commercializes with Biogen and is already approved for marketing in the US and other countries, became the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Therapy Areas